Sanofi throws weight behind ALS startup in $88M round
A second Big Pharma firm has invested in a startup developing medicines for amyotrophic lateral sclerosis, or ALS. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 9, 2023 Category: American Health Authors: Rowan Walrath Source Type: news
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round
Financing supports clinical activities for Company's two lead programs in ALS and pipeline development
CAMBRIDGE, Mass., March 9, 2023 -- (Healthcare Sales & Marketing Network) -- ... Biopharmaceuticals, Neurology, Venture Capital QurAlis , amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 9, 2023 Category: Pharmaceuticals Source Type: news
Bruce Willis Has Frontotemporal Dementia. Here ’ s What It Is
In an Instagram post, Bruce Willis’ family revealed that the actor has been diagnosed with frontotemporal dementia (FTD). The diagnosis comes nearly a year after his family revealed Willis has aphasia, which is characterized by difficulty speaking.
“Since we announced Bruce’s diagnosis of aphasia in spring 2022, Bruce’s condition has progressed and we now have a more specific diagnosis: frontotemporal dementia (known as FTD),” the family said in its statement, which was also posted on the Association for Frontotemporal Degeneration’s website.
Here’s what to know about the condition...
Source: TIME: Health - February 17, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Disease Explainer healthscienceclimate Source Type: news
Innovative ALS research fueled by $25 million from NIH
<img width="100" src="https://factor.niehs.nih.gov/sites/niehs-factor/files/styles/large/public/2020/7/science-highlights/als/thumb894442.jpg?itok=sqWo-nyw" /><br /><p>New initiative encourages research to transform treatment and prevention of amyotrophic lateral sclerosis, a devastating disease.</p>
(read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - February 3, 2023 Category: Environmental Health Source Type: news
Study links viral infections to Alzheimer ’s, Parkinson’s—with many caveats
A massive data mining study has found numerous associations between common viruses like the flu and devastating neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease). The findings expand on previous research linking individual viruses to neurological diseases. But experts caution that the study, which relied on electronic medical records rather than biological samples, merely describes correlations and doesn’t prove causation.
Still, it’s “really exciting,” says Kristen Funk, a neuroimmunologist who studi...
Source: ScienceNOW - January 19, 2023 Category: Science Source Type: news
“Running Bitcoin” half marathon will commemorate Hal Finney
Fran Finney, the widow of early Bitcoin contributor Hal Finney, announced a charity half marathon in honor of her husband via Twitter on Dec. 27. The event is called “Running Bitcoin.” It aims to collect funds for research into treatment for ALS, or amyotrophic lateral sclerosis. Hal Finney was…#twitter #als #halfinney #satoshinakamoto #elonmusks #runningbitcoin #cryptoslate #franfinney (Source: Reuters: Health)
Source: Reuters: Health - December 28, 2022 Category: Consumer Health News Source Type: news
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
NEW YORK, Dec. 27, 2022 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the U.S. Food and Drug Administ... Regenerative Medicine, Neurology, FDA BrainStorm Cell Therapeutics, NurOwn, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 27, 2022 Category: Pharmaceuticals Source Type: news
Analysis of accidental falls and the integration in the chronicity programs of patients with amyotrophic lateral sclerosis - Castro-Rodr íguez E, Azagra-Ledesma R, Gómez-Batiste Alertón X, Aguyé-Batista A, Zwart-Salmerón M, Cabanas-Valdés R, Caballero-Gómez FM, Clemente-Azagra C.
INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is the most common degenerative motor neuron disease. There is no curative treatment available, and these patients require multidisciplinary support to promote their comfort and quality of life. PAT... (Source: SafetyLit)
Source: SafetyLit - November 14, 2022 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
NEW YORK, Nov. 10, 2022 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the company has received a refusal to fil... Biopharmaceuticals, Regenerative Medicine, Neurology, FDA BrainStorm Cell Therapeutics, NurOwn, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 10, 2022 Category: Pharmaceuticals Source Type: news
Why I Voted 'Yes' on the New ALS Drug -- Twice
(MedPage Today) -- Recordings of both the first (March 30, 2022) and second (September 7, 2022) meetings of the Peripheral and Central Nervous System Advisory Committee to discuss AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 25, 2022 Category: Neurology Source Type: news
Cellular'Fix' Treatment Shows Promise Against ALS in Small Study
THURSDAY, Oct. 20, 2022 -- Researchers have made early progress toward a new approach to treating the deadly brain disease amyotrophic lateral sclerosis (ALS): using patients ' own immune system T cells.
ALS is a rare condition that kills nerve... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 20, 2022 Category: General Medicine Source Type: news
New ALS drug: What you need to know
The FDA recently approved the first new medication for amyotrophic lateral sclerosis in five years — despite uncertainty about how much it helps patients. (Source: Yale Science and Health News)
Source: Yale Science and Health News - October 17, 2022 Category: Universities & Medical Training Source Type: news
Why I Voted 'No' on the New ALS Drug
(MedPage Today) -- In March and September 2022, I served on an FDA Advisory Committee reviewing the application of Amylyx Pharmaceuticals for the novel drug AMX0035 for patients with amyotrophic lateral sclerosis (ALS).
I voted against approval... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 13, 2022 Category: American Health Source Type: news
Winnipeg woman who chose to die with medical assistance said struggle for home care help led to decision
Sathya Dhara Kovac, 44, died on Monday through the medical assistance in dying program. She had amyotrophic lateral sclerosis and told loved ones she wanted to live longer, but felt she had no other choice given barriers she faced getting enough home care support. (Source: CBC | Health)
Source: CBC | Health - October 4, 2022 Category: Consumer Health News Tags: News/Canada/Manitoba Source Type: news
Newly Approved ALS Drug Relyvrio To Face Its Next Challenge: Pricing And Reimbursement
There's a swirl of controversy around FDA's approval of Relyvrio, a new drug indicated for ALS (amyotrophic lateral sclerosis), often called Lou Gehrig's Disease. But there are also pricing and reimbursement issues the drug will face as its sponsor, Amylyx Pharmaceuticals, pursues market uptake. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 4, 2022 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
